Complications of pregnancy and XXXX development after cessation of treatment with @entity4446 for @entity29 .

@entity1 @entity2208 @entity154 @entity3465 @entity7275 @entity245 @entity29 @entity4446 @entity5849
PURPOSE: @entity4446 ( @entity7275 ) has proven efficacy in the therapy of @entity29 . Its teratogenicity is demonstrated in animal studies when used at very high doses, whereas @entity1 data suggest that @entity7275 at maintenance doses is safe. We report the outcome of 72 pregnancies in @entity1 with @entity29 who were previously treated with @entity7275 with three different doses of 50, 75, and 100 mg/d, for a median duration of 18 months, along with long-term follow-up of the @entity1 . METHODS: We have compared the outcome of pregnancies and development of the offspring in the following two groups: group 1, @entity1 with @entity29 who conceived 6 months to 22 years after stopping @entity7275 (median 72 months); and group 2, @entity1 with @entity29 who never received @entity7275 prior to conception. All pregnancies were evaluated in terms of outcome: live full-term birth, @entity3465 , stillbirth, @entity2208 , @entity5849 , and therapeutic dilatation and curettage. Data on @entity1 were obtained regarding birth weight, @entity154 , and development. RESULTS: Group 1 included 72 pregnancies carried by 29 @entity1 . There were 51 live births (4 premature), 16 @entity2208 , 1 stillbirth, 2 therapeutic abortions due to abnormal amniocentesis, and 2 ectopic pregnancies. The total incidence of fetal loss was 29.2%. In group 2, 75 @entity1 had 140 pregnancies resulting in 120 live births (8 premature), 18 @entity2208 , and 2 stillbirths. There were no cases of ectopic pregnancies or abnormal amniocentesis. The total incidence of fetal loss was 14.3%. There was no increase in the incidence of @entity245 when the mothers had been treated with @entity7275 prior to pregnancy. CONCLUSIONS: The incidence of fetal loss is higher in @entity1 with @entity29 who had been previously treated with @entity7275 compared with those who had not. Whether this was related to the older age at conception in @entity7275 group, longer duration of disease, initially more severe disease, or use of @entity7275 we cannot tell.
